You are here

Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B

Last updated on February 21, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hemophilia B
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Patients with moderate to severe hemophilia B ( having acute hemorrhage or requiring "short-term therapy" for intermittent secondary
prophylaxis regimens.

2. HIV seropositive ( asymptomatic) or seronegative subjects.

3. No history or detectable inhibitors.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Patients with moderate to severe hemophilia B ( having acute hemorrhage or requiring "short-term therapy" for intermittent secondary
prophylaxis regimens.

2. HIV seropositive ( asymptomatic) or seronegative subjects.

3. No history or detectable inhibitors.

NCT00581126
Pfizer
Completed
Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now